

Press Release

Presentation at the AACR 2023

Biomunex Pharmaceuticals, a French company specialized in immunotherapy, presents the latest preclinical results on its disruptive MAIT cell redirection approach for cancer treatment at the 2023 AACR¹ Annual Meeting

- **Biomunex, a company focused on the discovery and development of innovative immunotherapies in oncology, has created and developed BiXAb[®], a unique, proprietary, best-in-class technological platform for the generation of bi- and multi-specific antibodies, enabling it to develop bispecific antibodies with high therapeutic potential for the treatment of many types of cancers, both solid and liquid, in a cost and time effective manner.**
- **Biomunex is the first company worldwide to focus on the development of a new class of bispecific antibodies capable of specifically engaging and redirecting MAIT cells, a subpopulation of T cells, naturally present in most tissues of the body, particularly in mucosal or barrier tissues.**
- **Data to be presented by Biomunex at AACR 2023 show that BiXAb based bispecific antibodies are able to specifically engage MAIT cells and redirect them to kill cancer cells. These "MAIT engagers" are particularly effective in the treatment of solid tumors, in contrast to conventional "CD3+ T cell engagers" and present a significantly better toxicity profile.**
- **The ability of MAIT engagers to activate only MAIT cells, without affecting the rest of the immune cells, limits the release of excessive cytokines which is the dose-limiting toxicity usually caused by conventional T Cell engagers targeting CD3.**

Paris (France), Cambridge (MA, USA). April 12th, 2023 - Biomunex Pharmaceuticals, a French biopharmaceutical company focused on the development of immunotherapies based on the discovery and development of bi- and multi-specific antibodies for the treatment of cancer, announced today that it will participate in and present new scientific data at the American Association for Cancer Research (AACR) annual meeting, which will take place from April 14th to April 19th, 2023 at the Orange County Convention Center, Orlando, Florida, USA.

During this meeting, **Dr. Simon Plyte, Chief Scientific Officer of Biomunex**, will present a poster entitled "*MAIT engagers: An efficacious novel modality in the field of T-cell engagers for the treatment of solid tumors*" during the "Therapeutic Antibodies 3" session, which will be held on Monday, April 17, 2023, from 1:30 p.m. to 5:30 p.m.

¹ AACR: American Association for Cancer Research

The presentation will be focused on recent data obtained by Biomunex, detailing the properties of bispecific antibodies generated through Biomunex' proprietary BiXAb® platform, and in particular their ability to specifically target and redirect MAIT cells (Mucosal Associated Invariant T cells), a new subpopulation of T cells, against tumor cells.

These data will also be compared to the performance of the *T cell engagers*, antibodies traditionally used in immunotherapy for the engagement and redirection of T cells against tumor cells. They support the scientific relevance of Biomunex' technology and the interest of developing immunotherapies based on the targeting and redirection of MAIT cells. First identified and described in 1999 by Dr. Olivier Lantz of the Institut Curie in France, scientific adviser to Biomunex, MAIT cells are a subpopulation of T cells naturally present in barrier tissues and mucosa.

Through its proprietary BiXAb platform, which enables the rapid development of bispecific antibodies, Biomunex has developed the world's first bispecific antibodies capable of targeting and redirecting MAIT cells to kill tumor cells. Unlike traditional T cell engagers, which target all CD3+ T cells, Biomunex' MAIT engagers target a MAIT cell-specific receptor, which allows them to activate only MAIT cells in the targeted tissues, thus avoiding the widespread release of cytokines and activation of the immunosuppressive regulatory T cells (Treg) in the tumor microenvironment. Based on these promising data, Biomunex has selected its first drug candidate and will soon start clinical trials to evaluate the first MAIT engagers.

"Unknown a few years ago, MAIT cells are now showing their strong potential for the treatment of a large number of solid tumors. We are very proud to be able to present these new data for the first time ever at such a prestigious event as the AACR meeting," said Dr. Pierre-Emmanuel Gerard, President, CEO and founder of Biomunex. "Biomunex now has solid assets to ensure the development and progression toward clinical phases of its first drug candidates designed to specifically engage and redirect MAIT cells. On the one hand, our best-in-class proprietary next generation bispecific antibody BiXAb® platform, allows us to rapidly develop bispecific antibodies ready to enter the clinical phase. On the other hand, our collaboration with renowned academic institutes and research centers, many of which are conducting advanced research on MAIT cells, gives us a clear advantage in the development of this new class of immunotherapies, which addresses major drawbacks of currently available immunotherapies."

"These data show the ability of MAIT cells to infiltrate and proliferate in cancerous tissue while maintaining cytotoxic activity to eliminate cancer cells. The unique approach developed by Biomunex, which allows us to activate MAIT cells without causing cytokine release syndrome and without the significant side effects associated with the use of traditional T-cell engagers, is a truly disruptive approach in cancer immunotherapy and we look forward to confirming these data with the evaluation of our future drug candidate in clinical trials," concluded Dr. Simon Plyte, Chief Scientific Officer of Biomunex.

Information about the presentation:

Title: MAIT engagers: An efficacious novel modality in the field of T-cell engagers for the treatment of solid tumors

Session Category: Immunology

Session Title: Therapeutic Antibodies 3

Session Date and Time: Monday Apr 17, 2023 1:30 PM - 5:00 PM

Location: Poster Section 24

Poster Board Number: 1

Published Abstract Number: 2954

About Biomunex Pharmaceuticals : www.biomunex.com

Biomunex Pharmaceuticals is a biopharmaceutical company based in Paris (France) and Cambridge, MA, USA, led by an international and experienced team of recognized advisors and experts.

Biomunex specializes in the discovery and development of breakthrough immunotherapeutic approaches, based on solid data and proven biological and clinical evidence, to address unmet medical needs in oncology.

Biomunex has created and developed BiXAb®, a robust, 'Plug and Play', next-generation bi- and multi-specific antibody technology platform, using a proprietary computational modeling approach, with a very robust IP and patent portfolio. The BiXAb platform, which allows the generation of bispecific antibodies from any pair of monoclonal antibodies in a simple, fast and cost-effective manner, has been validated through licensing agreements and collaborations with the pharmaceutical and biotech industry.

Biomunex is also the first company worldwide to develop an immuno-oncology approach that allows, through bispecific antibodies derived from its BiXAb platform, to specifically target, engage and redirect MAIT cells, a subpopulation of T cells naturally present throughout the body, most specifically in mucosal and barrier tissues, to kill cancer cells, for the treatment of solid tumors.

Medias contacts:

NewCap

Arthur Rouillé

arouille@newcap.fr

+33 (0)1 44 71 00 15